ERS 2020 — Real-world efficacy of benralizumab in severe eosinophilic asthma


  • Pavankumar Kamat
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Preliminary findings of a real-world study showed that benralizumab significantly reduced exacerbation rates in patients with severe eosinophilic asthma (SEA), including those with chronic rhinosinusitis with nasal polyps (CRwNP). 

Why this matters

  • Although the safety and efficacy of benralizumab have been established in phase 3 trials, its real-world data are limited.

Study design

  • Interim analysis (n=61) of the multicentre retrospective ANANKE study which evaluates the clinical characteristics and asthma exacerbations in patients with SEA receiving 12 weeks of benralizumab treatment.
  • The median follow-up duration was 9.3 (interquartile range, 6.1-11.7) months. 
  • Annualized exacerbation rates (AER) were assessed before and after the first injection of benralizumab (index date). 
  • Funding: AstraZeneca.

Key results

  • 34.4% of the patients had CRwNP in the past year.
  • The AER was 4.98 for any exacerbation and 1.25 for severe exacerbations during the year before the index date.
  • At follow-up, the AER decreased to 0.38 for any exacerbation (reduction of 92.4%) and 0.08 for severe exacerbations (reduction of 93.6%).

Limitations

  • The study is ongoing.
  • Retrospective design.